Home> Products> Inhibitors> Efonidipine hydrochloride monoethanolate-CAS 111011-76-8
price inquiry for CAS:111011-76-8, Product:Efonidipine hydrochloride monoethanolate
For research use only. We do not sell to patients.

Efonidipine hydrochloride monoethanolate CAS: 111011-76-8

Category: Inhibitors
Product Name: Efonidipine hydrochloride monoethanolate
Cat No: I000446
CAS No: 111011-76-8
Synonyms: NZ-105
Molecular Formula: C34H38N3O7P.HCl.C2H5OH
Molecular Weight: 714.18
SMILES: O=P1(C2=C(C)NC(C)=C(C(OCCN(C3=CC=CC=C3)CC4=CC=CC=C4)=O)[C@@H]2C5=CC=CC([N+]([O-])=O)=C5)OCC(C)(C)CO1.OCC.Cl
Solubility: DMSO: ≤ 8.5 mg/mL
Target: Calcium Channel
Storage: Desiccate at +4°C
CAS 111011-76-8,Efonidipine hydrochloride monoethanolate
  • Description

Efonidipine(NZ-105) Hcl monoethanolate is a dual T-type and L-type calcium channel blocker (CCB).

in vitro: Efonidipine and nifedipine, but not other examined CCBs, also increased the N(6), 2'-O-dibutyryladenosine 3',5'-cyclic monophosphate (dbcAMP)-induced StAR mRNA, which reflects the action of adrenocorticotropic hormone, and efonidipine and R(-)-efonidipine enhanced the dbcAMP-induced DHEA-S production in NCI-H295R adrenocortical carcinoma cells [1]. I(Ca(T)) was blocked mainly by a tonic manner by nifedipine, by a use-dependent manner by mibefradil, and by a combination of both manners by efonidipine. IC50s of these Ca2+ channel antagonists to I(Ca(T)) and L-type Ca2+ channel current (I(Ca(L))) were 1.2 micromol/l and 0.14 nmol/l for nifedipine; 0.87 and 1.4 micromol/l for mibefradil, and 0.35 micromol/l and 1.8 nmol/l for efonidipine, respectively [4]. 

in vivo: Twenty hypertensive patients on chronic hemodialysis were given efonidipine 20-60 mg twice daily and amlodipine 2.5-7.5 mg once daily for 12 weeks each in a random crossover manner. The average blood pressure was comparable between the efonidipine and amlodipine periods (151 + or - 15/77 + or - 8 versus 153 + or - 15/76 + or - 8 mmHg). The pulse rate did not change significantly during the administration periods [2]. In the UM-X7.1 group, EFO treatment significantly attenuated the decrease of LVEF without affecting blood pressure compared with the vehicle group. EFO treatment decreased heart rate (by approximately 10%) in both groups [3].

  • References

[1]. Ikeda K, et al. Efonidipine, a Ca(2+)-channel blocker, enhances the production of dehydroepiandrosterone sulfate in NCI-H295R human adrenocortical carcinoma cells. Tohoku J Exp Med. 2011;224(4):263-71. 

[2]. Nakano N, et al. Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients. Int Heart J. 2010 May;51(3):188-92. 

[3]. Suzuki S, et al. Beneficial effects of the dual L- and T-type Ca2+ channel blocker efonidipine on cardiomyopathic hamsters. Circ J. 2007 Dec;71(12):1970-6. 

[4]. Lee TS, et al. Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20.


price inquiry for CAS:111011-76-8, Product:Efonidipine hydrochloride monoethanolate